top of page
_edited.jpg

Type 2 Diabetes
Medication Study

For overweight adults with cardiovascular OR kidney disease

Clinical trial evaluating the efficacy of an oral medication in adults who have T2D and who are overweight.

Eastside Research Associates has partnered with a sponsor to study the effectiveness of an oral investigational medication vs. insulin in the management of type 2 diabetes in individuals who are overweight and have a diagnosis of cardiovascular disease and/or kidney disease. Participants have a 50/50 chance of receiving the investigational medication or insulin.
 

Participants enrolled in this new clinical research study receive, free of cost, either the investigational medication or insulin, medical evaluations and follow ups. Participants will also be compensated for their time. 

Participant Enrollment Criteria
  • 18 years of age or older

  • Diagnosed with type 2 diabetes 

  • On a stable dose of at least one oral diabetes mediation

  • Diagnosed with cardiovascular disease and/or kidney disease

  • BMI greater than or equal to 25

  • Additional criteria apply

Participants Will Receive
  • Up to $5,000 for study completion. 

  • Investigational medication or insulin, blood tests and medical evaluations under the care of a physician.

Location and Time
  • ~2 years

  • Eastside Research Associates in Redmond, WA

Once you complete the self-screening questionnaire, our expert recruiting team will call and discuss the outline of the study, time commitment and compensation plan. Once enrolled, participants will be under the careful guidance and care of our physicians and clinical staff for monitoring and data collection through the duration of the study.

If you are interested in participating in this study or have questions about your eligibility, please use the form below or contact our study recruitment team.

Interested in future studies?

Join our participant list using the link below if you are interested in becoming a study participant for other current or future studies offered by ERA.

bottom of page